Where the GLP-1 compounding fight stands: 5 things to know
AI Summary
In a recent report, compounding pharmacies are finding ways around the FDA's ban on producing cheaper versions of GLP-1 drugs like Ozempic and Wegovy by adding vitamins or supplements to their formulations. This legal maneuver suggests that the loophole allowing cheaper mass production is narrowing. The implications are significant for patients seeking affordable alternatives to these popular diabetes and weight-loss medications, as well as for the ongoing regulatory debate surrounding drug pricing and access.
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.